A comprehensive Lancet review details how GLP-1 drugs have expanded from diabetes treatment to proven benefits in obesity, cardiovascular disease, heart failure, kidney disease, liver disease, and sleep apnea, with next-generation multi-agonists promising even greater efficacy.
8+ proven indications and growingGLP-1 drugs now have evidence for diabetes, obesity, cardiovascular events, heart failure, kidney disease, liver disease, sleep apnea, and osteoarthritis
What the researchers found
GLP-1 receptor agonists provide: highly effective glycemic control with low hypoglycemia risk; significant weight loss; reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death); reduced heart failure hospitalizations; reduced albuminuria and slowed eGFR decline (kidney protection); prevention of type 2 diabetes in obesity; regression of liver steatosis and prevention of fibrosis; and symptomatic improvement in obstructive sleep apnea and knee osteoarthritis.
Next-generation developments include: dual GLP-1-glucagon and GLP-1-amylin agonists; triple GIP-GLP-1-glucagon agonists with greater weight loss potential; small-molecule oral GLP-1 agonists; and exploration of neurodegenerative disease and substance use disorder indications.
Why it matters
This Lancet review captures a historic moment in medicine: a single drug class transforming the treatment of multiple major diseases simultaneously. GLP-1 drugs are arguably the most impactful pharmaceutical development of the past decade, and next-generation multi-agonists may amplify these benefits further. Understanding the full scope of their proven and emerging applications is essential for every clinician.
How the study worked
Comprehensive narrative review published in The Lancet, synthesizing evidence from major clinical trials, cardiovascular outcome studies, and current development pipelines for GLP-1-based therapies.
What this study cannot tell us
As a narrative review, this does not include systematic methodology or meta-analysis. Some mentioned benefits (neurodegenerative diseases, substance use disorders) have only suggestive evidence. Gastrointestinal adverse events remain a significant clinical challenge. Long-term safety data for the newest formulations is limited. Access and cost barriers are not addressed but represent major real-world implementation challenges.
How to read the evidence
Published in The Lancet — one of the world's highest-impact medical journals — this review synthesizes evidence from large randomized controlled trials including major cardiovascular outcome studies. The evidence for core indications (diabetes, obesity, cardiovascular protection) is extremely strong; evidence for newer indications varies in maturity.
When this study was published
Published in 2026, this is the most current comprehensive review of GLP-1 therapeutics, capturing the latest trial data and pipeline developments.
The bigger picture
GLP-1-based therapies represent a paradigm shift in medicine — from single-disease drugs to multi-system therapeutics. The development trajectory from mono-agonists to dual and triple agonists mirrors the field's ambition to maximize metabolic benefits. With oral formulations and new indications on the horizon, these peptide drugs may become the most widely prescribed medication class in history.
Questions still open
- Will triple GIP-GLP-1-glucagon agonists deliver on their promise of superior weight loss without unacceptable GI side effects?
- Can oral small-molecule GLP-1 agonists achieve efficacy comparable to injectable formulations?
- Will clinical trials confirm the suggestive benefits for Alzheimer's disease and substance use disorders?
Common questions
What conditions can GLP-1 drugs now treat beyond diabetes?
What are next-generation GLP-1 drugs and how are they different?
Read the original research
Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
Lancet (London, England), 407(10531), 892-908
Citation
Nauck, Michael A; Tuttle, Katherine R; Tschöp, Matthias H; Blüher, Matthias. (2026). Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.. Lancet (London, England), 407(10531), 892-908. https://doi.org/10.1016/S0140-6736(25)02105-1